{"denoms":[{"counts":[{"groupId":"BG000","value":"374"},{"groupId":"BG001","value":"372"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"755"}],"units":"Participants"}],"groups":[{"description":"Randomized participants received 120 mg of belzutifan orally once daily (QD), until disease progression or discontinuation.","id":"BG000","title":"Belzutifan"},{"description":"Randomized participants received 10 mg of Everolimus orally QD, until disease progression or discontinuation.","id":"BG001","title":"Everolimus"},{"description":"Non-Randomized participants enrolled into the Safety Run-in received up to 120 mg of belzutifan QD.","id":"BG002","title":"Safety Run-In"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.2","value":"61.6"},{"groupId":"BG001","spread":"9.7","value":"63.1"},{"groupId":"BG002","spread":"6.6","value":"70.0"},{"groupId":"BG003","spread":"10.0","value":"62.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"169"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"284"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"586"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"78"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"300"},{"groupId":"BG001","value":"303"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"612"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"65"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"99"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"291"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"588"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"17"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"37"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"84"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"171"}],"title":"Favorable"},{"measurements":[{"groupId":"BG000","value":"248"},{"groupId":"BG001","value":"242"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"493"}],"title":"Intermediate"},{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"91"}],"title":"Poor"}]}],"description":"Stratification factor per case report form based on the following risk factors: baseline Karnofsky Performance Status \\<80%; interval between initial diagnosis of renal cell carcinoma to start of first-line systemic treatment for advanced disease \\<1year; baseline hemoglobin \\<lower limit of normal (LLN); baseline platelet count \\>upper limit of normal (ULN); baseline corrected serum calcium \\>ULN; and baseline neutrophil \\>ULN. The category was determined by totaling the risk factors per participant: favorable (0 factors); intermediate (1-2 factors); and poor (≥3 factors).","paramType":"COUNT_OF_PARTICIPANTS","title":"International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Risk Category","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"186"},{"groupId":"BG001","value":"190"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"379"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"188"},{"groupId":"BG001","value":"182"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"376"}],"title":"2-3"}]}],"description":"Stratification factor per case report form, the number of prior VEGF/VEGF-Receptor targeted therapies that they received to treat their advanced Renal Cell Carcinoma (RCC): 1 versus 2-3.","paramType":"COUNT_OF_PARTICIPANTS","title":"Number of Prior Vascular Endothelial Growth Factor (VEGF)/VEGF-Receptor Targeted Therapies","unitOfMeasure":"Participants"}],"populationDescription":"Per protocol, the 9 participants enrolled in the Safety Run-In were not randomized and not included in the protocol-specified analyses for any of the outcome measures."}